Effects of Treatments for Anemia and Iron Deficiency on the Electrolyte Balance in Lung Transplant Recipients: A Special Focus on Hypophosphatemia

Hypophosphatemia Clinical Trial

Official title:

Effects of Treatments for Anemia and Iron Deficiency on the Electrolyte Balance in Lung Transplant Recipients: A Special Focus on Hypophosphatemia

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06112236
• Other study ID #: 2022-02302
• Status: Active, not recruiting
• Start date: February 17, 2023
• Est. completion date: March 31, 2027

Study information

• Verified date: October 2023
• Source: University of Zurich
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to generate evidence regarding hypophosphatemia after iron infusion in lung transplant recipients in context of anemia and/or iron deficiency.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 250
• Est. completion date: March 31, 2027
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• lung transplant recipient

• treated at the University Hospital Zurich between 2015 until 2022

Exclusion Criteria:

• Denied general consent

Related Conditions & MeSH terms

• Hypophosphatemia

Intervention

Other:
• no intervention
no intervention

Locations

Country	Name	City	State
Switzerland	University Hospital Zurich	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of serum phosphate level	Change of serum phosphate level before and after iron infusion	Baseline and up to 90 days after iron infusion
Secondary	Change of urin phosphate level	Change of urin phosphate level before and after iron infusion	Baseline and up to 90 days after iron infusion
Secondary	Change of hemoglobin	Change of hemoglobin level before and after iron infusion	Baseline and up to 90 days after iron infusion
Secondary	Change of mean corpuscular volume (MCV)	Changes of serum MCV level before and after iron infusion	Baseline and up to 90 days after iron infusion
Secondary	Change of mean corpuscular hemoglobin (MCH)	Change of serum MCH level before and after iron infusion	Baseline and up to 90 days after iron infusion
Secondary	Change of serum magnesium	Change of serum magnesium level before and after iron infusion	Baseline and up to 90 days after iron infusion
Secondary	Change of serum and urin calcium	Change of serum and urin calcium level before and after iron infusion	Baseline and up to 90 days after iron infusion
Secondary	Change of serum albumin	Change of serum albumin level before and after iron infusion	Baseline and up to 90 days after iron infusion
Secondary	Complications after iron infusion	Number of patients with complications due to hypophosphatemia after iron infusion (Hospitalization, hypoxia, fracture due to hypophosphatemia)	2015-2022
Secondary	Predictors	Analysis of possible predictors for the decrease of serum phosphate levels after iron infusion	baseline and up to 90 days after iron infusion
Secondary	Therapeutic management	Descriptive analysis of therapeutic management of hypophosphatemia after iron infusion	2015 to 2022